FectinMoreTM 是经优化设计的针对贴壁细胞的非脂质体阳离子聚合物转染试剂，用于 DNA 或 RNA 转染。FectinMoreTM 可与细胞表面的蛋白多糖结合，通过细胞吞饮作用进入细胞，形成的转染试剂-目标核酸复合体在胞质中释放。FectinMoreTM适合贴壁细胞转染，也能转染一些难转细胞，操作简单，高效低毒。
操作步骤： (依据上表以 24 孔板为例，DNA 转染） 1、准备待转染细胞：按照贴壁细胞 5×104/孔的密度接种于 24 孔板中，37 ℃培养过夜。 2、转染前 30 分钟，将待转细胞更换新鲜无血清培养基。 3、准备 FectinMore/DNA 复合物：将 0.5μg DNA 溶于 25μL 无血清培养基中混匀，再将 1.5 μL FectinMore 加入另外 25 μL 无血清培养基中混匀，各自于室温反应 5 分钟后，再将两者混匀后得到的 50μL 复合物室温孵育 15 分钟。 4、转染：将上述 FectinMore/DNA 复合物加入每孔细胞（含无血清细胞培养基 450 μL），复合物占总体积的 1/10，轻柔摇匀。37 ℃孵育 24-48 小时。必要时，转染 6 小时后可更换新鲜有血清培养基。

引用文献：

1. Rapid SARS-CoV-2 Spike Protein Detection by Carbon Nanotube-Based Near-Infrared Nanosensors. Nano Lett. 2021 Mar 10;21(5):2272-2280. (IF 11.189)
2. Vitamin D-Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription. Clin Cancer Res. 2018 Jul 1;24(13):3217-3228.(IF 10.107)
3. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8.Theranostics. 2019; 9(24): 7168–7183.(IF 8.579)
4. TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Molecular Oncology. 21 January 2020, Pages 928-945.(IF 6.574)
5. Macrophage migration inhibitory factor has a permissive role in concanavalin A-induced cell death of human hepatoma cells through autophagy. Cell Death Dis. 2015 Dec 3;6:e2008.(IF 6.304)
6. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.Cell Death & Disease. volume 10, Article number: 322 (2019).(IF 6.304)
7. Phosphofructokinase 1 Platelet Isoform Promotes β-Catenin Transactivation for Tumor Development. Front Oncol. 2020 Mar 5;10:211. (IF 6.244)
8. TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer.Cancers. 2019, 11(2), 210.(IF 6.126)
9. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.Cell Physiol Biochem. 2018;51:337–355.(IF 5.5)
10. ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex. Transl Res. 2016 Sep;175:129-143.e13.(IF 5.411)
11. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF‐κB‐mediated IKKβ expression.International Journal of Cancer. Volume141, Issue11, 1 December 2017,Pages 2305-2317.(IF 5.145)
12. Minocycline suppresses dengue virus replication by down-regulation of macrophage migration inhibitory factor-induced autophagy. Antiviral Research. 155 (2018) 28–38.(IF 4.101)
13. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterology. 2016 Jun 14; 22(22): 5183–5192.(IF 3.655)
14. Depletion of UXT, a novel TSG101 interaction protein, leads to enhanced CEP55 attenuation through lysosome degradation. Biochem Biophys Res Commun. 2021 Jan 21;542:59-64. (IF 3.575)
15. Hsa_circ_0005075 predicts a poor prognosis and acts as an oncogene in colorectal cancer via activating Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3311-3319. (IF 3.507)
16. Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells. PLoS One. 2021 Jul 8;16(7):e0254011. (3.24)
17. Role of Dicer in regulating oxaliplatin resistance of colon cancer cells.Biochemical and Biophysical Research Communications..Volume 506, Issue 1, 17 November 2018, Pages 87-93.(IF 2.985)
18. NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1. International Journal of Medical Sciences. 2020; 17(14): 2214–2224.(IF 2.523)
19. Long non-coding RNA TMPO-AS1 promotes tumor progression via sponging miR-140-5p in breast cancer. Exp Ther Med. 2021 Jan;21(1):17. (IF 2.477)
20. Macrophage migration inhibitory factor induces vascular leakage via autophagy. Biol Open. 2015 Feb 15; 4(2): 244–252.(IF 2.029)